Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies

被引：18

作者：

Tabrizi, Mohammad ^{[1
]}

Funelas, Cherryl ^{[2
]}

Suria, Hamza ^{[3
]}

机构：

[1] AnaptysBio Inc, Preclin Dev, San Diego, CA 92121 USA

[2] Takeda San Francisco, Bioanalyt Dev, San Francisco, CA USA

[3] AnaptysBio Inc, Corp Dev, San Diego, CA 92121 USA

来源：

AAPS JOURNAL | 2010年 / 12卷 / 04期

关键词：

monoclonal antibodies; pharmacodynamics (PD); pharmacokinetics (PK); quantitative pharmacology; translational strategies; DEPENDENT CELLULAR CYTOTOXICITY; ENDOTHELIAL GROWTH-FACTOR; KAPPA-B LIGAND; POPULATION PHARMACOKINETICS; PHASE-I; RECEPTOR ACTIVATOR; MULTIPLE-MYELOMA; BONE METASTASES; CANCER-PATIENTS; HIGH-AFFINITY;

D O I：

10.1208/s12248-010-9220-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose- and concentration-response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure-response relationships early on.

引用

页码：592 / 601

页数：10

共 50 条

[21] Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development
Kaur, Harleen
CRITICAL REVIEWS IN BIOTECHNOLOGY, 2021, 41 (02) : 300 - 315
[22] Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, Jie
Zhou, Honghui
Jiao, Qun
Davis, Hugh M.
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12) : 1382 - 1402
[23] Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
Betts, Alison
van der Graaf, Piet H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 528 - 541
[24] Development and application of monoclonal antibodies against the mycotoxin mycophenolic acid
Dietrich, Richard
Maertlbauer, Erwin
MYCOTOXIN RESEARCH, 2015, 31 (04) : 185 - 190
[25] Development and application of monoclonal antibodies against the mycotoxin mycophenolic acid
Richard Dietrich
Erwin Märtlbauer
Mycotoxin Research, 2015, 31 : 185 - 190
[26] Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
Arias-Pinilla, Gustavo A.
Modjtahedi, Helmout
CANCERS, 2021, 13 (08)
[27] In situ production of therapeutic monoclonal antibodies
Suscovich, Todd J.
Alter, Galit
EXPERT REVIEW OF VACCINES, 2015, 14 (02) : 205 - 219
[28] Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
Temrikar, Zaid H.
Suryawanshi, Satyendra
Meibohm, Bernd
PEDIATRIC DRUGS, 2020, 22 (02) : 199 - 216
[29] Monoclonal antibodies as therapeutic tools in cancer
Mezzanzanica, D
Canevari, S
MINERVA BIOTECNOLOGICA, 1999, 11 (04) : 295 - 301
[30] Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, Ron J.
Huitema, Alwin D. R.
Schellens, Jan H. M.
Beijnen, Jos H.
CLINICAL PHARMACOKINETICS, 2010, 49 (08) : 493 - 507

← 1 2 3 4 5 →